Short Interest in Mainz Biomed (NASDAQ:MYNZ) Grows By 61.2%

Mainz Biomed (NASDAQ:MYNZ) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 128,500 shares, an increase of 61.2% from the February 28th total of 79,700 shares. Based on an average daily trading volume, of 214,900 shares, the days-to-cover ratio is presently 0.6 days. Currently, 6.1% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Maxim Group initiated coverage on Mainz Biomed in a report on Friday, February 14th. They issued a “buy” rating and a $14.00 price objective on the stock.

Mainz Biomed Stock Performance

Shares of Mainz Biomed stock traded down $0.48 during trading on Monday, hitting $3.10. 208,345 shares of the stock were exchanged, compared to its average volume of 96,812. The stock has a market cap of $6.21 million, a PE ratio of -0.05 and a beta of 0.33. The stock’s fifty day moving average is $5.40 and its 200 day moving average is $7.32. Mainz Biomed has a 12 month low of $2.87 and a 12 month high of $45.20.

Institutional Investors Weigh In On Mainz Biomed

A hedge fund recently bought a new stake in Mainz Biomed stock. Virtu Financial LLC purchased a new position in Mainz Biomed (NASDAQ:MYNZ) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed at the end of the most recent quarter.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.